Biogen Inc. (BIIB): Capital Expenditures
$153.80M
Year ended 2025-12-31
$167.90M
Trailing 12 months to 2026-03-31
-13.8%
3-year compound annual growth
-18.4%
5-year compound annual growth
-13.3%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $153.80M | +0.1% | 2026-02-06, From 2025-01-01 |
| 2024-12-31 | $153.70M | -44.5% | 2026-02-06, From 2024-01-01 |
| 2023-12-31 | $277.00M | +15.3% | 2026-02-06, From 2023-01-01 |
| 2022-12-31 | $240.30M | -6.9% | 2025-02-12, From 2022-01-01 |
| 2021-12-31 | $258.10M | -39.2% | 2024-02-14, From 2021-01-01 |
| 2020-12-31 | $424.80M | -17.4% | 2023-02-15, From 2020-01-01 |
| 2019-12-31 | $514.50M | -33.2% | 2022-02-03, From 2019-01-01 |
| 2018-12-31 | $770.60M | -11.2% | 2021-02-03, From 2018-01-01 |
| 2017-12-31 | $867.40M | +40.8% | 2020-02-06, From 2017-01-01 |
| 2016-12-31 | $616.10M | -4.2% | 2019-02-06, From 2016-01-01 |
| 2015-12-31 | $643.00M | +123.4% | 2018-02-01, From 2015-01-01 |
| 2014-12-31 | $287.80M | +16.8% | 2017-02-02, From 2014-01-01 |
| 2013-12-31 | $246.30M | -3.2% | 2016-02-03, From 2013-01-01 |
| 2012-12-31 | $254.55M | +22.4% | 2015-02-04, From 2012-01-01 |
| 2011-12-31 | $208.02M | +20.2% | 2014-02-06, From 2011-01-01 |
| 2010-12-31 | $173.06M | +4.5% | 2013-02-05, From 2010-01-01 |
| 2009-12-31 | $165.65M | -40.0% | 2012-02-03, From 2009-01-01 |
| 2008-12-31 | $275.95M | -2.9% | 2011-02-04, From 2008-01-01 |
| 2007-12-31 | $284.11M | n/a | 2010-02-09, From 2007-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Biogen Inc. (BIIB) | 2025-12-31 | $153.80M | +0.1% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $563.00M | +7.6% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $34.00M | -11.0% |
| Amgen Inc (AMGN) | 2025-12-31 | $1.86B | +69.5% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $8.43M | -70.4% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $201.05M | +20.3% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $192.00M | -81.7% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $6.97M | -34.8% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $28.85M | -7.0% |
Compare BIIB, GILD, NBIX, AMGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗